CTRI/2015/09/006203进行中（未招募）3 期
A Multi-centric, Prospective, Randomized, Double- blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 / 4 mg as Compared to Pioglitazone in Type 2 Diabetes Mellitus
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,140
- 试验地点
- 41
- 主要终点
- Change from baseline in glycosylated hemoglobin (HbA1c) for
研究概览
简要总结
A Phase III of 12 week duration to evaluate the efficacy and safety of Saroglitazar in diabetic dyslipidemic patients not controlled with atorvastatin 10 mg revealed statistically significant reduction in the TG levels as compared to placebo. Statistically significant reduction in the LDL cholesterol, total cholesterol and apolipoprotein B levels with Saroglitazar 4 mg was observed as compared to baseline. Thus far,Saroglitazar clinical studies have included mild to moderate dyslipidemic patients and showed favorable effects .
The preclinical and clinical experience of Saroglitazar showed favourable effects not only on lipid profile but also glycemic control. . Thus based on the result of above studies the present study is proposed to assess the effects of 2 mg and 4 mg of Saroglitazar as compared to Pioglitazone 30 mg in patients with T2DM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant, Investigator and Outcome Assessor Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Subjects age 18- 75 years, of either sex.
- •Documented history of type 2 diabetes mellitus defined by ADA criteria.
- •History of stable metformin dose atleast since last 6 weeks (total daily dose should not exceed 2 gm) in conjunction with diet and exercise.
- •Fasting plasma glucose ≤270 mg/dL (14.98 mmol/L).
- •HbA1c should be ≥7.5%.
- •Subject has given informed consent for participation in this trial.
排除标准
- •Type 1 diabetes mellitus or a history of ketoacidosis or secondary forms of diabetes.
- •Subjects who have been treated with insulin for ≥7 days within 3 months prior to the screening visit.
- •History of recurrent or severe hypoglycemia within in last 3 months.
- •History of acute or chronic metabolic acidosis, including diabetic ketoacidosis.
- •Subjects on glitazone / glitazar therapy in the past 1 month.
- •History of uncontrolled thyroid disorder, not controlled by thyroid modulating drugs.
- •Subjects with coronary insufficiency (e.g., a myocardial infarction, a coronary angioplasty or bypass graft, unstable angina, transient ischemic attacks, or a documented cerebrovascular accident within 6 months prior to the screening visit).
- •Subjects with cardiac failure or history of cardiac failure (New York Heart Association [NYHA] Stages 3 to 4).
- •Uncontrolled hypertension (BP160/100 mmHg).
- •History of cancer (except non-melanoma skin cancer) or unexplained haematuria.
- •Subjects with an alanine transaminase (ALT) level ≥2.5 times the upper normal limit (UNL), active liver disease, or jaundice.
- •Subject with systemic corticosteroid therapy for 2 week within past 3 months or history of chronic or recurrent use.
- •History of any hemoglobinopathy (such as hemolytic anemia or sickle cell disease) that may affect determination of HbA1c.
- •Subjects with microscopic hematuria.
- •History of AIDS / HIV infection.
- •History of viral hepatitis B or C.
- •Pregnant or breastfeeding female.
- •Subjects with any medical condition that may complicate participation in the trial.
- •Subjects who is unsuitable for the study according to the investigator.
- •Subjects who have participated in any trial in past 3 months.
- •Subjects who are unable to understand and give informed consent.
结局指标
主要结局
Change from baseline in glycosylated hemoglobin (HbA1c) for
时间窗: Week 24
Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg
时间窗: Week 24
次要结局
- Comparision of Change from baseline in glycosylated hemoglobin((HbA1c) between Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg)
- Change from baseline in glycosylated hemoglobin (HbA1c) for(Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg)
- Comparision of Change from baseline in fasting plasma glucose between(Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg)
- Change from baseline in fasting plasma glucose for Saroglitazar 4 mg, 2(mg and Pioglitazone 30 mg)
- Change from baseline in 2 hour postprandial plasma glucose for(Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg)
- Change from baseline in lipid profile and lipoprotein.(Triglyceride (TG) cholesterol)
研究者
研究点 (41)
Loading locations...
相似试验
已完成
3 期
Study of Muraglitazar Versus Pioglitazone in Type 2 DiabetesType 2 Diabetes MellitusNCT00106808Bristol-Myers Squibb1,440
已完成
3 期
Sitagliptin Added-on to Insulin Study (0431-051)Type 2 Diabetes MellitusNCT00395343Merck Sharp & Dohme LLC641
已完成
3 期
Long-term Study of SYR-472Diabetes MellitusNCT01431807Takeda680
已完成
3 期
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).Type 2 Diabetes MellitusNCT02033889Merck Sharp & Dohme LLC621
终止
3 期
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone AloneDiabetes Mellitus, Type 2NCT01089790Forest Laboratories141